Vergote I - Search Results

1

Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer.

Despierre E, Moisse M, Yesilyurt B, Sehouli J, Braicu I, Mahner S, Castillo-Tong DC, Zeillinger R, Lambrechts S, Leunen K, Amant F, Moerman P, Lambrechts D, Vergote I. Despierre E, et al. Among authors: vergote i. Gynecol Oncol. 2014 Dec;135(3):415-22. doi: 10.1016/j.ygyno.2014.09.014. Epub 2014 Oct 2. Gynecol Oncol. 2014. PMID: 25281495

2

Case report: mixed germ cell tumour of the ovary presenting as a missed abortion.

Vergote IB, Witters I, Moerman P, Timmerman D, Spitz B, Van Assche FA. Vergote IB, et al. Eur J Gynaecol Oncol. 1996;17(6):518-9. Eur J Gynaecol Oncol. 1996. PMID: 8971532 No abstract available.

3

Malignant trophoblastic disease following a twin pregnancy consisting of a complete hydatiform mole and a normal fetus and placenta. A case report.

Vandeginste S, Vergote IB, Hanssens M, Moerman P, Page G, Van Den Berghe K, Van Assche A. Vandeginste S, et al. Among authors: vergote ib. Eur J Gynaecol Oncol. 1999;20(2):105-7. Eur J Gynaecol Oncol. 1999. PMID: 10376424

4

Incidence of positive peritoneal cytology in low-risk endometrial cancer treated by laparoscopically assisted vaginal hysterectomy.

Vergote I, De Smet I, Amant F. Vergote I, et al. Gynecol Oncol. 2002 Mar;84(3):537-8. doi: 10.1006/gyno.2001.6422. Gynecol Oncol. 2002. PMID: 11855893 No abstract available.

5

Laparoscopic lower para-aortic staging lymphadenectomy in stage IB2, II, and III cervical cancer.

Vergote I, Amant F, Berteloot P, Van Gramberen M. Vergote I, et al. Int J Gynecol Cancer. 2002 Jan-Feb;12(1):22-6. doi: 10.1046/j.1525-1438.2002.01070.x. Int J Gynecol Cancer. 2002. PMID: 11860532

6

PTEN mutation analysis in uterine leiomyosarcomas and mixed mullerian sarcomas.

Amant F, Vergote I. Amant F, et al. Among authors: vergote i. Am J Obstet Gynecol. 2002 Jul;187(1):258. doi: 10.1067/mob.2002.124942. Am J Obstet Gynecol. 2002. PMID: 12114928 No abstract available.

7

Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study.

Keldsen N, Havsteen H, Vergote I, Bertelsen K, Jakobsen A. Keldsen N, et al. Among authors: vergote i. Gynecol Oncol. 2003 Feb;88(2):118-22. doi: 10.1016/s0090-8258(02)00103-8. Gynecol Oncol. 2003. PMID: 12586589 Clinical Trial.

8

Ethnic variations in uterine leiomyoma biology are not caused by differences in myometrial estrogen receptor alpha levels.

Amant F, Huys E, Geurts-Moespot A, Lindeque BG, Vergote I, Sweep F, Schoenmakers EF. Amant F, et al. Among authors: vergote i. J Soc Gynecol Investig. 2003 Feb;10(2):105-9. doi: 10.1016/s1071-5576(02)00253-8. J Soc Gynecol Investig. 2003. PMID: 12594000

9

Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.

D'Agostino G, Amant F, Berteloot P, Scambia G, Vergote I. D'Agostino G, et al. Among authors: vergote i. Gynecol Oncol. 2003 Mar;88(3):266-9. doi: 10.1016/s0090-8258(03)00011-8. Gynecol Oncol. 2003. PMID: 12648573 Clinical Trial.

10

Endometrial stromal sarcoma with a sole t(X;17) chromosome change: report of a case and review of the literature.

Amant F, Moerman P, Cadron I, Hagemeijer A, Vergote I, Debiec-Rychter M. Amant F, et al. Among authors: vergote i. Gynecol Oncol. 2003 Mar;88(3):459-62. doi: 10.1016/s0090-8258(02)00096-3. Gynecol Oncol. 2003. PMID: 12648605 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

888 results

Search Page

Filters